The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer
Open accessAbstract
// Qingyun Liu 1, * , Zubin Yu 2, * , Shuai Yuan 1, * , Weijia Xie 1 , Chengying Li 1 , Zeyao Hu 1 , Ying Xiang 1 , Na Wu 1 , Long Wu 1 , Li Bai 3, ** , Yafei Li 1, ** 1 Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, People’s Republic of China 2 Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, People’s Republic of China 3 Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, People’s Republic of China * These authors have contributed equally to this work ** These authors jointly directed the project Correspondence to: Yafei Li, email: liyafei2008@hotmail.com Keywords: non-small-cell lung cancer (NSCLC), exosome, miRNAs, prognosis, biomarker Received: June 29, 2016 Accepted: December 05, 2016 Published: December 30, 2016 ABSTRACT Exosomal miRNAs are proposed as excellent candidate biomarkers for clinical applications. However, little is known about their potential roles as prognostic biomarkers in lung cancer. In this study, we explored the prognostic value of plasma exosomal microRNAs (miRNAs) for non-small-cell lung cancer (NSCLC). Using a quantitative polymerase chain reaction (qPCR) array panel, we analyzed 84 plasma exosomal miRNAs in 10 lung adenocarcinoma patients and 10 matched healthy controls. The qPCR array showed 30 aberrantly expressed exosomal miRNAs. Nine candidate miRNAs were selected based on differential expression and previous reports for further evaluating their prognostic roles in 196 NSCLC patients. Elevated levels of exosomal miR-23b-3p, miR-10b-5p and miR-21-5p were independently associated with poor overall survival (with hazard ratio [95% confidence interval]: 2.42 (1.45 - 4.04), P = 0.001; 2.22 (1.18 - 4.16), P = 0.013; 2.12 (1.28 - 3.49), P = 0.003, respectively). When compared to the clinical prognostic variables only model, adding the three exosomal miRNA signatures significantly improved survival predictive accuracy with an increase of time-dependent area under the receiver operating characteristic curve from 0.88 to 0.91 (P=0.015). Our results indicated that plasma exosomal miR-23b-3p, miR-10b-5p and miR-21-5p are promising non-invasive prognostic biomarkers of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedR: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Cited by
Doyle, L., & Wang, M. (2019) · Cells · doi:10.3390/cells8070727 · Cited by 3,236
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S. M., & Voinea, S. C. (2020) · Cells · doi:10.3390/cells9020276 · Cited by 1,344
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Effect of exosomal miRNA on cancer biology and clinical applications
Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800
Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis
De Rubis, G., Rajeev Krishnan, S., & Bebawy, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.006 · Cited by 535
Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage
Wang, H., Peng, R., Wang, J., Qin, Z., & Xue, L. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0492-1 · Cited by 527
MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance
Iqbal, M. A., Arora, S., Prakasam, G., Calin, G. A., & Syed, M. A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.003 · Cited by 449
Zhang, R., Xia, Y., Wang, Z., Zheng, J., Chen, Y., Li, X., Wang, Y., & Ming, H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.055 · Cited by 295
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Stejskal, P., Goodarzi, H., Srovnal, J., Hajdúch, M., van ’t Veer, L. J., & Magbanua, M. J. M. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01710-w · Cited by 278
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
Russano, M., Napolitano, A., Ribelli, G., Iuliani, M., Simonetti, S., Citarella, F., Pantano, F., Dell’Aquila, E., Anesi, C., Silvestris, N., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01601-2 · Cited by 260
Li, M.-Y., Liu, L.-Z., & Dong, M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01312-y · Cited by 215
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
Recommendations for Cell-Free DNA Assay Validations
Lockwood, C. M., Borsu, L., Cankovic, M., Earle, J. S. L., Gocke, C. D., Hameed, M., Jordan, D., Lopategui, J. R., Pullambhatla, M., Reuther, J., et al. (2023) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.09.004 · Cited by 96
MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes
Elemeery, M. N., Mohamed, M. A., Madkour, M. A., Shamseya, M. M., Issa, N. M., Badr, A. N., Ghareeb, D. A., & Pan, C.-H. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i42.6322 · Cited by 25
Metadata
- Authors
- Liu, Q., Yu, Z., Yuan, S., Xie, W., Li, C., Hu, Z., Xiang, Y., Wu, N., Wu, L., Bai, L., & Li, Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-30
- Volume
- 8
- Issue
- 8
- Pages
- 13048-13058
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2564567999
- Cited by
- 258
- References
- 65
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.